Time trends in multidrug-resistant tuberculosis

D. Falzon, M. Zignol (Geneva, Switzerland)

Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview

Session: MDR- and XDR-TB: epidemiological and public health overview
Session type: Oral Presentation
Number: 200

Disease area: Respiratory infections

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Falzon, M. Zignol (Geneva, Switzerland). Time trends in multidrug-resistant tuberculosis. Eur Respir J 2012; 40: Suppl. 56, 200

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Trends of multidrug-resistant tuberculosis clustering in Portugal Source: ERJ Open Res, 5 (1) 00151-2018; 10.1183/23120541.00151-2018 Year: 2019
Analysis of multidrug-resistant tuberculosis Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 1 Year: 2014
Determinants of multidrug-resistant tuberculosis (MDR-TB) in Belarus Source: Annual Congress 2012 - MDR- and XDR-TB: epidemiological and public health overview Year: 2012
Comorbidome in multidrug-resistant tuberculosis patients Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020
HIV and multidrug-resistant tuberculosis: overlapping epidemics Source: Eur Respir J 2014; 44: 251-254 Year: 2014
Surgical treatment of multidrug-resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 523s Year: 2003
Evaluation of treatment outcomes for multidrug-resistant tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 312s Year: 2001
Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis Source: Eur Respir J 2015; 46: 444-455 Year: 2015
Extensively drug-resistant tuberculosis (XDR-TB) and multidrug-resistant tuberculosis (MDR-TB): a retrospective comparative study Source: Annual Congress 2008 - Multidrug-resistant and the emerging threat of extensively drug-resistant tuberculosis Year: 2008
Management and treatment of multidrug-resistant tuberculosis Source: International Congress 2019 – Tuberculosis: latest advances and challenges in patient management Year: 2019
Multidrug-resistant tuberculosis in a tuberculosis unit – results of five years Source: Eur Respir J 2006; 28: Suppl. 50, 377s Year: 2006
Transmission of multidrug-resistant and extensively drug-resistant tuberculosis in a metropolitan city Source: Eur Respir J 2013; 41: 901-908 Year: 2013
Predictors of treatment outcome in multidrug-resistant tuberculosis in Portugal Source: Eur Respir J 2013; 42: 1747-1749 Year: 2013
Multidrug-resistant tuberculosis (MDR-TB) Source: Breathe 2010; 6: 283 Year: 2010
PG2 Multidrug-resistant tuberculosis management in settings with a low tuberculosis incidence Source: Milan 2017 - Educational material Year: 2017
Long-term treatment outcomes in multidrug-resistant tuberculosis (MDR-TB) Source: Annual Congress 2007 - Drug-resistant and multidrug-resistant tuberculosis Year: 2007
Resistance genotypes of multidrug-resistant Mycobacterium tuberculosis isolates in Serbia Source: International Congress 2019 – Tuberculosis and non-TB mycobacterial infection II Year: 2019
Risk factors for multidrug-resistant and extensively drug-resistant tuberculosis in Estonia Source: Annual Congress 2008 - The challenge of multidrug-resistant tuberculosis Year: 2008
Predictors of treatment outcome in multidrug-resistant tuberculosis Source: Annual Congress 2011 - Risk factors and treatment outcomes in multidrug- and extensively drug-resistant tuberculosis Year: 2011
Multidrug-resistant tuberculosis Source: Annual Congress 2008 - The thoracic surgeon facing infection Year: 2008